Post Profile






DNA sequencing could open up new drug indications for patients with rare cancers

(European Society for Medical Oncology) Thanks to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers, but who carry the same genetic mutations.
read more

share

Related Posts


Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option

Health : Medical News Today

Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with ...

Tiny barcodes provide huge advance in personalized cancer therapy

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Researchers are using synthetic DNA sequences as the tiniest of barcodes to determine which anticancer drugs will work best for each individual patient. It's all done within the patient’s tumor, and before treatment even begins.

Annual flu jab may pose greater risk for lung cancer patients under immunotherapy

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study m...

England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in pati...

Impact of cognitive functions on oral cancer therapies

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) The development of oral cancer drugs as a modality therapy over the last decade has highlighted the problem of non-adherence. Only cancer drugs that are taken can actually work.

Comments


Copyright © 2016 Regator, LLC